This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ariad Forced to Shutter Vital Study of Iclusig Due to Toxicity

CAMBRIDGE, Mass (TheStreet) -- Blood clots and heart-related side effects have now forced Ariad Pharmaceuticals ( (ARIA - Get Report)) to shut down a vital clinical trial involving its leukemia drug Iclusig, the company said Friday.

Ariad shares are down 33% to $3 in early Friday trading.

The so-called EPIC study was designed to compare Iclusig to Novartis' ( (NVS - Get Report)) Gleevec in patients with newly diagnosed chronic myeloid leukemia (CML). Right now, Iclusig is used primarily in CML patients who no longer respond to first- and second-line therapies. If positive, the EPIC trial could have helped Ariad convince doctors to use Iclusig in earlier-stage CML patients, thereby greatly increasing sales.

Ariad's plan is now shot because of Iclusig's toxicity. The EPIC study is being discontinued because too many patients treated with the drug were reporting blood clots, the company said. 

The decision to shutter the EPIC trial comes 10 days after Ariad stopped enrolling new patients into the study for the same heart-related safety concerns. The FDA has issued a warning to doctors about Iclusig's cardiac-related toxicity, although the drug has not been pulled from the market. 

Ariad's stock price is down more than 80% since the company first admitted Iclusig's significant toxicity.

If Iclusig remains on the market, the drug will likely be used only in CML patients who have failed other treatments, or in a small subset of patients with a genetic mutation known as T35i. 

 

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARIA $9.00 -1.32%
NVS $104.25 0.70%
YHOO $43.07 -0.71%
AAPL $131.78 -0.20%
FB $80.14 -0.50%

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs